Design, Synthesis, and Biological Investigation of Novel Classes of 3-Carene-Derived Potent Inhibitors of TDP1. by Il'ina, IV et al.
molecules
Article
Design, Synthesis, and Biological Investigation of
Novel Classes of 3-Carene-Derived Potent Inhibitors
of TDP1
Irina V. Il’ina 1, Nadezhda S. Dyrkheeva 2, Alexandra L. Zakharenko 2, Alexander Yu. Sidorenko 3,
Nikolay S. Li-Zhulanov 1,4, Dina V. Korchagina 1, Raina Chand 5, Daniel M. Ayine-Tora 5,
Arina A. Chepanova 2, Olga D. Zakharova 2, Ekaterina S. Ilina 2, Jóhannes Reynisson 6 ,
Anastasia A. Malakhova 2,7 , Sergey P. Medvedev 7,8 , Suren M. Zakian 4,7,
Konstantin P. Volcho 1,4,* , Nariman F. Salakhutdinov 1,4 and Olga I. Lavrik 2,4
1 N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences,
9, Lavrentiev Ave., 630090 Novosibirsk, Russia; ilyina@nioch.nsc.ru (I.V.I.); lizhulan@nioch.nsc.ru (N.S.L.-Z.);
korchaga@nioch.nsc.ru (D.V.K.); anvar@nioch.nsc.ru (N.F.S.)
2 Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences,
8, Lavrentiev Ave., 630090 Novosibirsk, Russia; elpida80@mail.ru (N.S.D.); sashaz@niboch.nsc.ru (A.L.Z.);
arinachepanova@mail.ru (A.A.C.); isar@niboch.nsc.ru (O.D.Z.); katya.plekhanova@gmail.com (E.S.I.);
amal@bionet.nsc.ru (A.A.M.); lavrik@niboch.nsc.ru (O.I.L.)
3 Institute of Chemistry of New Materials of National Academy of Sciences of Belarus, Skaryna Str, 36,
220141 Minsk, Belarus; camphene@gmail.com
4 Nstitute of Cytology and Genetics, The Siberian Division of the Russian Academy of Sciences,
Novosibirsk State University, 2, Pirogova Str., 630090 Novosibirsk, Russia; zakian@bionet.nsc.ru
5 School of Chemical Sciences, The University of Auckland, Private Bag 92019, Victoria Street West,
Auckland 1142, New Zealand; rcha387@aucklanduni.ac.nz (R.C.); dayi479@aucklanduni.ac.nz (D.M.A.-T.)
6 School of Pharmacy and Bioengineering, Keele University, Hornbeam Building, Staffordshire ST5 5BG, UK;
j.reynisson@keele.ac.uk
7 Federal Research Centre Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences,
10, Lavrentiev Ave, 630090 Novosibirsk, Russia; medvedev@bionet.nsc.ru
8 E.Meshalkin National medical research center of the Ministry of Health of the Russian Federation,
15 Rechkunovskaya Str., 630055 Novosibirsk, Russia
* Correspondence: volcho@nioch.nsc.ru; Tel.: +44-0-178-2733-985
Academic Editors: Wolfgang Sippl and Maria Emília de Sousa
Received: 11 May 2020; Accepted: 31 July 2020; Published: 31 July 2020


Abstract: Two novel structural types of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors
with hexahydroisobenzofuran 11 and 3-oxabicyclo [3.3.1]nonane 12 scaffolds were discovered.
These monoterpene-derived compounds were synthesized through preliminary isomerization of
(+)-3-carene to (+)-2-carene followed by reaction with heteroaromatic aldehydes. All the compounds
inhibit the TDP1 enzyme at micro- and submicromolar levels, with the most potent compound
having an IC50 value of 0.65 µM. TDP1 is an important DNA repair enzyme and a promising
target for the development of new chemosensitizing agents. A panel of isogenic clones of the
HEK293FT cell line knockout for the TDP1 gene was created using the CRISPR-Cas9 system.
Cytotoxic effects of topotecan (Tpc) and non-cytotoxic compounds of the new structures were
investigated separately and jointly in the TDP1 gene knockout cells. For two TDP1 inhibitors, 11h and
12k, a synergistic effect was observed with Tpc in the HEK293FT cells but was not found in TDP1 −/−
cells. Thus, it is likely that the synergistic effect is caused by inhibition of TDP1. Synergy was also
found for 11h in other cancer cell lines. Thus, sensitizing cancer cells using a non-cytotoxic drug
can enhance the efficacy of currently used pharmaceuticals and, concomitantly, reduce toxic side effects.
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1. Introduction
There are a number of unresolved issues regarding chemotherapeutic treatment for oncological
diseases, for example, low efficiency, resistance of malignant tumors, side effects, and high toxic load.
The cytotoxic effect of chemotherapy is caused by DNA damage, and the ability of cancer cells to repair
DNA lesions results in resistance. Therefore, the development of DNA repair enzyme inhibitors is a
promising strategy to improve the efficacy of DNA damaging agents in clinical use.
Tyrosyl-DNA-phosphodiesterase 1 (TDP1) is a DNA repair enzyme and a promising therapeutic
target to enhance established cancer treatment [1–4]. TDP1 plays a key role in the removal of DNA
lesions, in particular those caused by DNA topoisomerase I (TOP1) inhibitors. TOP1 is an essential
enzyme that regulates DNA topology by reducing DNA supercoiling. TOP1 introduces a transient
single-strand break in DNA, enabling the broken strand to rotate around the TOP1-bound DNA
during fundamental cellular events, such as replication, transcription, and repair [5]. TOP1 inhibitors,
for example, topotecan (Tpc) and irinotecan, both important chemotherapeutic agents, stabilize the
cleavage complex TOP1–DNA, leading to cell death [6]. However, TDP1 removes the stalled TOP1-DNA
complex, reducing the efficacy of the drugs and leading to resistance [7–9]. As has been confirmed in
gene knockout studies in mice and human cell lines, TDP1 contributes to the development of drug
resistance in a number of cancers (see [3] and references therein). Indeed, human cell lines with mutant
or missing TDP1 as well as TDP1-knockout mice are both hypersensitive to the well-established TOP1
inhibitor camptothecin and its derivatives. Conversely, at high TDP1 expression levels, camptothecin
and etoposide cause limited DNA damage [3]. Thus, a promising approach to increase the selectivity
and potency of TOP1 poisons to cancer cells is to combine them with TDP1 inhibitors, which can
significantly increase the chemotherapeutic efficacy.
In recent years, TDP1 inhibitors of various chemical types have been discovered [1–4],
including natural products, such as usnic [10–12] and bile acids [13] (for example, compounds 1
and 2, Figure 1).
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Monoterpenes, which have a unique diverse structure and are inexpensive, available and often
enantiomerically pure, is an attractive renewable material for the development of physiologically
active agents [14]. One of the approaches to utilize various monoterpenes, such as pinenes and
p-menthenes, is their capability to react with carbonyl compounds, mainly aldehydes, resulting in
heterocyclic compounds of different structural types [14,15]. Some of these derivatives exhibit
analgesic, antiviral, neuroprotective, and antitumor properties [14]. Moreover, new classes of
TDP1 inhibitors with submicromolar half maximal inhibitory concentration (IC50) values have been
developed that contain monoterpene moieties; for example, coumarin [16], 4-arylcoumarin [17],
and adamantane [18–21] derivatives as well as octahydro-2H-chromenes 3 (see Figure 1) synthesized
from p-menthane monoterpenoid (-)-isopulegol [22]. Their ability to enhance the Tpc cytotoxic
potential was demonstrated for several of these derivatives. For example, 7-hydroxycoumarin
derivative 4 (Figure 1) with a pinene-type fragment reduced the CC50 (median cytotoxic concentration
causing 50% cell death) of camptothecin eight-fold for the human breast adenocarcinoma cell line
MCF-7 [16] while the hybrid molecule 5, comprising of (4-fluorophenyl)-coumarin and geraniol
moieties, showed a significant increase in the antitumor effect of Tpc on Krebs-2 ascites in an in vivo
tumor model [17]. Among the adamantane derivatives, strong synergism was found for 6 and 7
(Figure 1), both containing the acyclic monoterpene substituents, when lung adenocarcinoma cells
A549 were treated in combination with Tpc [18,20].
Monoterpene (+)-3-carene 8 (Scheme 1) is one of the main components of turpentine. Nevertheless,
this compound is very rarely considered as a molecular platform for the development of new
therapeutics and never considered for TDP1 inhibitors. In the current work, we studied the
anti-TDP1 activity of (+)-3-carene derivatives for the first time. Two sets of (+)-3-carene derivatives
with hexahydroisobenzofuran and 3-oxabicyclo [3.3.1]nonane skeletons were synthesized through
preliminary isomerization of 3-carene to 2-carene followed by reaction with aldehydes. As a result,
new structural types of potent TDP1 inhibitors were discovered. Furthermore, to elucidate the
inhibitors’ mechanism of action on the cellular level, a panel of HEK293FT TDP1 knockout isogenic
clones was created using the CRISPR-Cas9 approach and the cytotoxic potentials were measured.
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2. Results and Discussion
2.1. Chemistry
It has been shown that carene can be successfully reacted with carbonyl compounds [23,24].
Previously, we showed that condensation of 2-carene 9 with aldehydes 10a–c in the presence of
montmorillonite clays led to the formation of hexahydroisobenzofurans 11a–c as a mixture of two
isomers at the C(1) position and compounds with 3-oxabicyclo[3.3.1]nonane structure 12 as minor
products (Scheme 1). It was found that hexahydroisobenzofuran 11a obtained with condensation of
2-carene 9 with 4-hydroxy-3-methoxybenzaldehyde 10a demonstrated potent neuroprotective activity
in an in vivo Parkinson model combined with low acute toxicity [24]. The reactions of 3-carene 8 with
aldehydes gave the same products 11 and 12 as it did for 2-carene 9 but in much lower yields (only 3%
for the reaction with aldehyde 10a), since 2-carene 9 is more reactive due to the conjugation of the
double bond with the cyclopropane ring [23].
Interestingly, 2-carene 9 is widely found in nature albeit in small concentrations. The isolation of
9 from essential oils, or from reaction mixtures after 3-carene 8 isomerization, is difficult, making 9
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expensive and therefore not attractive for use in organic synthesis [25–29]. Recently, we developed
a method for the isomerization of readily available 3-carene 8 to 2-carene 9 using montmorillonite
clays as a catalyst [30]. It was demonstrated that a mixture of carenes, limonene, and terpinenes
containing 10% 2-carene can be effectively used as a starting material instead of pure 2-carene in a
clay-catalyzed reaction with 4-hydroxy-3-methoxybenzaldehyde 10a, resulting in chiral isobenzofurans
11a. The largest yield of 11a was obtained with the 2-carene-containing mixture (60%) [31], which is
much higher than using pure 2-carene 9 (33%). At the same time, condensation of carenes with
aldehydes has not yet been systematically studied. Here, we synthesized heterocyclic compounds
using 2-carene from a mixture containing carenes, limonene, and terpinenes with 2-carene comprising
10%, by condensation with heteroaromatic furan and thiophene aldehydes. The choice of this aldehyde
was based on the presence of furan and thiophene moieties in many bioactive compounds, including
TDP1 inhibitors [32–35], as well as preliminary molecular modelling that indicated favourable binding
to TDP1.
For the synthesis of heterocyclic compounds, we used a mixture of terpenes obtained by the
isomerization of 3-carene 8 in the presence of montmorillonite K10 [31], which consists of 10% 2-carene,
30% 3-carene, 20% m- and p-cymols, 12% terpinenes, 5% limonene, and a number of dimeric compounds
(m/z = 272) (according to gas chromatography-mass spectrometry (GC-MS) data). The reaction pathways
for 3-carene isomerization are shown in Scheme S1, Supplementary Material.
At first, we carried out the reactions with 4-hydroxy-3-methoxybenzaldehyde 10a and
crotonaldehyde 10c previously studied using the 2-carene-containing mixture instead of neat 2-carene
9 [23]. In the present work, we used montmorillonite clay K10 as a catalyst, and the reaction
was carried out without solvent at room temperature for 20 h. As a result of the reaction of
4-hydroxy-3-methoxybenzaldehyde 10a and the 2-carene-containing mixture, isobenzofurans 11a
were obtained, which are diastereomers at position C(1) ((S)-/(R)- = 1:1, total yield 81%). In addition,
compound 12a (11%) was isolated (Scheme 2, Table 1).
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R RCHO Product 11 (Yield,(S)-/(R) Ratio
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(Total Yield, %, 12/13)
4-Hydroxy-3-methoxyphenyl 10a 11a (81%, (S)-/(R) = 1:1) 12a (11%)
(E)-prop-1-en-1-yl 10c 11c (89%, (S)-/(R) = 1.3:1)
Thiophen-2-yl 10d 11d (78%, (S)-isomer) 12d, 13d (5%, 7:1)
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5-Nitrofuran-2-yl 10j - 12j (18%)
Thi p en-3-yl 10k 11k (91%, (S)-/(R) = 1.5:1) 12k (21%)
The reactants for the products with the 3-oxabicyclo[3.3.1]nonane framework 12a in reactions of
the 2-carene-containing mixture with aldehydes can be both 2- and 3-carene as well as limonene and
possibly terpinenes [15,23]; a proposed reaction mechanism for compounds 11, 12, and 13 is shown in
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Scheme 3. The yields for 11, 12, and 13 were calculated based on the 2-carene concentration in the
mixture and on the total concentration of carenes, limonene, and terpinenes.
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3-oxabicyclo[3.3.1]nonane framework is well studied [15,23], the only example of isolating a compound
with an exocyclic double bond is the reaction of α-terpineol 14 with benzaldehyde in the presence of
BF3∗Et2O, leading to 3d [36].
The reaction of the 2-carene-c ntaining mixtur with methyl-substituted
thiophene-2-carboxaldehydes 10e and 10f is similar to the previously entioned reactions.
Thus, starting from 3-methylthiophene-2-carboxaldehyde 10e, compounds 11e and 12e were
synthesized with yields of 86% and 2%, respectively; compound 13e was formed only in trace amounts.
Compound 11f (85%) and a mixture of 12f and 13f (12f/13f = 3:1, 2%) were obtained in the reaction
with 5-methylthiophene-2-carboxaldehyde 10f. Compounds 11h and 12h were synthesized with
yields of 73% and 35%, respectively, using 5-bromothiophen-2-carboxaldehyde 10h. The reaction of the
2-carene-containing mixture with 4-bromothiophen-2-carboxaldehyde 10g proceeded quite differently,
as the only product of this reaction was compound 12g with the 3-oxabicyclo[3.3.1]nonane framework
with a 20% yield.
Molecules 2020, 25, 3496 6 of 22
When 5-nitro-substituted heteroaromatic aldehydes were reacted with the 2-carene-containing
mixture, compounds with the 3-oxabicyclo[3.3.1]nonane framework were only obtained. This can
be explained by the low ability for protonation by these aldehydes, leading to high-energy barriers
for the first stage of the isobenzofuran formation path (Scheme 3). Thus, by the reaction with
5-nitrothiophene-2-carboxaldehyde 13i and 5-nitro-2-furaldehyde 13j, compounds 12i, 13i (18%,
12i/13i = 5:1), and 12j (18%) were synthesized.
Interestingly, reaction of the 2-caren-containing mixture with 3-thiophenecarboxaldehyde 11k,
the isomer of 2-thiophenecarboxaldehyde 10d, proceeded in a non-stereoseletive way with the formation
of 11k as a pair of diastereomers at the substituent position at C(1) in the ratio (S)-11k/(R)-11k = 1.5:1,
with a total yield of 91%. Additionally, compound 12k with 3-oxabicyclo[3.3.1]nonane skeletone (21%)
was isolated from the reaction mixture.
It should be noted that in the case of the 2-carene-containing mixture reactions with aldehydes 10,
the main or even the only way of isobenzofuran synthesis was the formation of (S)-isomers (excluding
the interaction with 4-hydroxy-3-methoxybenzaldehyde 10a). Predominant formation of the (S)-isomer
of isobenzofuran was clearly observed for the condensation of 2-carene and anisaldehyde [37].
According to denstity functional theory (DFT) calculations, the formation of (S)-isomer is energetically
more favorable (by 6.8 kJ/mol) compared to formation of the (R)-isomer [37]. Moreover, the lower
stability of the (R)-isomer in comparison with the (S)-isomer due to secondary transformations, leading
to resinofication under the reaction conditions compared with (S)-isomer, was also shown [37].
Reactions of 2- and 3-furaldehyde as well as pyrrole-2-carboxaldehyde with the 2-carene-containing
mixture did not lead to the formation of the target heterocyclic compounds. According to GC-MS
data, after the reactions, 2-carene remained unconverted, but limonene was completely consumed
and traces of compounds with m/z values corresponding to the intermolecular products, most likely
with the 3-oxabicyclo[3.3.1]nonane skeleton, were observed. Apparently, the intermolecular products
formed during the reaction are unstable and undergo degradation in the presence of an acid catalyst.
It should be noted that unreacted monoterpenes and other substances from the 2-carene-containing
mixture are easily separated from the more polar condensation products by column chromatography
using hexane as an elute. Moreover, compounds with the 3-oxabicyclo[3.3.1]nonane sceletone 12 can
also be synthesized based on more available limonene [15]. For example, condensation of limonene
with 2-thiophenecarboxaldehyde 10d catalyzed by montmorillonite K10 without solvent at room
temperature after 2 h led to the formation of compounds 12d and 13d (total yield 64%, 12d/13d = 14:1).
Thus, we obtained a wide range of hydrogenated isobenzofuran and 3-oxabicyclo[3.3.1]nonane
heterocycles, including compounds with an exocyclic double bond.
2.2. Biology
2.2.1. Structure–Activity Relationship Analysis
The compounds synthesized starting from (+)-3-carene 8 were tested for their TDP1 inhibitory
properties by measuring their IC50 values using a real-time fluorescent oligonucleotide biosensor [38].
This biosensor demonstrated high sensitivity and specificity for the detection of TDP1 activity.
The commercially available TDP1 inhibitor furamidine, a bisbenzamidine derivative belonging to
the diamidines family [34], was used as a positive control (IC50 1.2 ± 0.3 µM). The results for all the
derivatives are summarized in Table 2.
Compounds 11a, 12a, and 11c with aromatic and alkyl substituents at position C(1) do not exhibit
activity against TDP1, while the IC50 values for substances with heterocyclic substituents varied from
0.65 (12g) to 28 µM (12j) (Table 2).
Both 11 and 12, with the thiophen-2-yl moiety, give good inhibition (IC50 values 4.85 µM (11d),
3.35 µM (12d)). The addition of a methyl group at the 3-position (compounds 11e, 12e) as well as at the
5-position (compound 11f) on the thiophene ring had no effect.
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Table 2. TDP1 inhibition potency of the 3-carene derivatives.
R Compound 11 IC501, µM Compound 12 IC501, µM
4-Hydroxy-3-methoxyphenyl 11a >20 12a >20
(E)-prop-1-en-1-yl 11c >20 - -
Thiophen-2-yl 11d 4.85 ± 1.06 12d 3.35 ± 1.06
3-Methylthiophen-2-yl 11e 3.6 ± 1.7 12e 2.25 ± 0.63
5-Methylthiophen-2-yl 11f 4.7 ± 2.0 - -
4-Bromothiophen-2-yl - - 12g 0.65 ± 0.22
5-Bromothiophen-2-yl 11h 0.75 ± 0.07 12h 1.75 ± 0.78
5-Nitrothiophen-2-yl - - 12i 14 ± 1
5-Nitrofuran-2-yl - - 12j 28 ± 10
Thiophen-3-yl 11k 1.60 ± 0.56 12k 1.20 ± 0.14
Furamidine 1.2 ± 0.3
1 IC50—half maximal inhibitory concentration.
The addition of bromine onto the heterocycle significantly increased the inhibition potency of the
ligands. Thus, compound 11h with a bromine atom at the 5-position of the thiophene ring had the
best activity in the submicromolar range of the hexahydroisobenzofurans (IC50 0.75 µM). From the
compounds with the 3-oxabicyclo[3.3.1]nonane skeleton, the most active was 4-bromine-substituted
compound 12g (IC50 0.65 µM). A bromine shift from position 4 to 5 from 12g to 12h decreased the
inhibition potency (IC50 1.75 µM); nevertheless, 12h is approximately two-fold more active than 12d,
which does not have substituents on the thiophene ring.
Higher activity of the 3-substituted thiophenes 11k and 12k in comparison with 2-substituted
thiophenes 11d and 12d was also observed. Interestingly, the 5-nitro-substituted thiophen- (12i) and
furan (12j) with a 3-oxabicyclo[3.3.1]nonane skeleton did not exhibit high activity against TDP1.
2.2.2. Cell Growth and Viability
Topotecan Cytotoxicity on HEK293FT Wild Type and TDP1−/− Cells
TDP1 plays an essential role in the resistance of cancer cells to antitumour TOP1-inhibiting drugs.
It was shown previously for HEK293 [39] and other cell lines that cells lacking TDP1 expression
exhibit hypersensitivity to camptothecin and its derivatives, such as Tpc [40]. To examine the potential
impact of TDP1 knockout on cell survival and dosing with the synthesized compounds, we generated
HEK293FT TDP1-deficient (TDP1−/−) cell line. Using a paired gRNA CRISPR-Cas9 strategy and
polymerase chain reaction (PCR) screening of cell clones, we obtained three clones containing deletions
in the first protein coding the exon of the TDP1 gene. PCR products obtained from cell clones containing
deletions were further cloned in a T-vector and 10 independent plasmid clones were sequenced by
the Sanger method. Alignments of these deletions with the wild-type TDP1 gene sequence showed
that modifications in all three clones lead to a shift in the reading frame of the gene and should lead
to impaired synthesis of TDP1 (Figure S1). Clone B2 was found to have a 197-bp deletion in one of
the TDP1 alleles, as well as a 16-bp deletion and T nucleotide insertion in the other allele; clone B5
carried 198-bp and 196-bp deletions; and the E3 clone had deletions of 197bp and 200bp. We treated
TDP1-proficient (wild-type, WT) and TDP1-deficient (TDP1−/−) cells with increasing concentrations of
Tpc. The results for all three clones are presented in Figure S2A. Clone E3 was selected for further
work as it has a homozigous deletion causing an open reading frame shift in both alleles of the TDP1
gene and demonstrated sensitivity to Tpc. Clone E3 TDP1 mRNA was confirmed to have a 197/200-bp
deletion causing the open reading frame shift (Figures S1, S2B). There is a deletion at the level of
genomic DNA (Figure S2B, lane 4) and only the mutant form was transcribed (Figure S2B, lane 7).
The clone E3 was subsequently screened by the biochemical assay for 3′-phosphotyrosyl cleavage
activity to identify detectable TDP1 activity in the cell extract (Figure S2C). None was found in contrast
to the control WT cell extract and purified TDP1.
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We analyzed, using a colorimetric test, the relative amount of viable cells after treating HEK293FT
WT and TDP1-deficient (TDP1−/−) cells with increasing concentrations of Tpc for 72 h. TDP1 knockout
reduced cell viability, where the IC50 values in H2O were 150 nM for TDP1−/− and 250 nM for WT cells
(Figure 2A); and in DMSO, they were 30 nM for TDP1−/− and 200 nM for WT cells. Next, we studied
WT and mutant cells’ live activity after Tpc treatment on the xCELLigence System (ACEA Biosciences,
USA) by the impedance-based assay. HEK293FT TDP1−/− cells were more sensitive to Tpc (Figure 2B).
After Tpc administration to the cells, an increase of the slope was seen, characterizing the velocity of
the cell growth with Tpc as compared to the control both for WT (red columns) and mutant cells (green
columns) (Figure S1, Supplementary Materials). The analysis of the averaged slope for the time period
of ~70 h after Tpc treatment showed that the slope decreased depending on the Tpc concentration
(Figure 2CII). The sharper decrease of the slope for the mutant cells than for the WT (compare the
histogram for the 0 and 0.05 µM Tpc concentration, ~1.5 times for WT cells (red) and ~6 times for
TDP1−/−cells (green)) also characterizes the higher sensitivity of the mutant to the TOP1 inhibitor. The
Tpc IC50 values determined by the impedance-based assay were 60 nM for WT and 20 nM for TDP1−/−
cells in H2O. There was a three-fold difference for these IC50 values, which is nearly the same as for
the colorimetric assay. The absolute values slightly differed for these methods and solvents, but still,
HEK293FT TDP1−/− cells showed a higher sensitivity to the TOP1 inhibitor Tpc, thus verifying the
contribution of TDP1 on cell survival.Molecules 2020, 25, 3496 9 of 23 
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lead to undesirable side effects. 
Figure 2. Topotecan (Tpc) cytotoxicity on HEK293FT WT and TDP1−/− knockout cells (A).
Dose-dependent action of Tpc by the colorimetric test (B). Dose-dependent action of Tpc on cell viability
by the impedance-bas d r al-time a y on the xCELLigence Syst m (C). The slope characterizing
the velocity of cell growth with Tpc compared to the control for WT (red columns) and mutant
cells (green columns): I) After the Tpc addition, II) 70 h after Tpc treatment. Real-time cell
analysis dem nstrates sensitivty to Tpc. Cell proliferation and viability are affected by different
Tpc concentrations in the growth medium.
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TDP1 Inhibitors’ Cytotoxicity on HEK293FT TDP1−/− Cells
An analysis of the intrinsic cytotoxicity of the synthesized compounds was performed on
HEK293FT WT and TDP1-deficient (TDP1−/−) cell lines by a colorimetric test. We tested eight
compounds with the highest TDP1 inhibitory activity: 11e (3.6 µM), 11h (0.75 µM), 11k (1.6 µM),
12d (IC50 3.35 µM), 12e (2.25 µM), 12g (0.65 µM), 12h (1.75 µM), and 12k (1.2 µM). Interestingly,
cytotoxicity was absent, or insignificant, in the range of concentrations (0.08–100 µM) for all the
compounds in both cell lines (Figure 3A). The absence of toxicity is very important since it will not
lead to undesirable side effects.Molecules 2020, 25, 3496 10 of 23 
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Figure 3. The TDP1 inhibitors’ intrinsic cytotoxicity on HEK293FT WT and TDP1−/− cells (A).
Dose-dependent action of the derivatives (B). Activity with topotecan (Tpc) against HEK293FT cells in
combination with 11h and 12k. The Tpc concentration was 30 nM for TDP1−/− and 200 nM for the
WT cells.
Next, we checked the influence of the eight most potent TDP1 inhibitors on the cytotoxic effect of
Tpc on the WT and mutant cell lines. We chose 30 and 700 nM Tpc concentrations for the TDP1−/−
and WT cells, respectively, which are close to the IC50 values for Tpc in DMSO in the colorimetric
assay (Figure 2A). Then, we selected two candidates (11h and 12k) for subsequent studies based on
their ability to inhibit TDP1 activity and lo cytotoxicity. We tested the HEK293FT cells’ viability
after treat ent ith 11h and 12k and in conjunction with Tpc in a concentration close to its IC50
value (30 nM for TDP1−/− and 200 nM for WT cells). Suppressed cell growth was displayed with the
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TDP1 inhibitors and Tpc on the WT cells; however, no effect was seen for Tpc in TDP1-deficient cells
(Figure 3B). Thus, the synergistic action of Tpc in conjunction with 11h and 12k on HEK293FT WT cells
is most likely due to the TDP1 inhibition making it the main target of action. The initial increase in cell
proliferation on the graphs up to the 20 µM concentration can be observed because we diluted the
inhibitor with the medium before adding it to the well plate. Thus, a stimulation effect at low inhibitor
concentrations could be observed due to the addition of fresh medium.
Activity of 11h and 12k with Topotecan against Tumor Cells
Next, we checked the cytotoxicity of the combination of Tpc with 11h and 12k against several
cancer cell lines and the results are shown in Figure 4.
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The intrinsic cyt toxicity of both 11h and 12k on HeLa (cer ical , ( colon
can er), IMR-32 (human euroblastoma cell ine), and Krebs-2 c l as low (Figure 4A).
Due to their low cytotoxicity, these deri cepted as being suitable for further study on
their cyt t ff , ). t ed o enhancement of the Tpc
ytotoxicity for e ll ( ata not shown). We compared HCT and IMR-32 cells’ viability after
treatment with 11h and 12k alone and in the presence f c i a concentration close to their IC50 values
(900 nM, HCT; and 8 nM, IMR-32 cells). We observed suppressed cell growth in the joint presence of
Tpc with 11h or 12k on the IMR-32 cells and no effect of Tpc on the HCT cell line (Figure 4B). We tested
HCT and IMR-32 cells’ viability after Tpc treatment in the absence and presence of 11h/12k (Figure 4C).
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Both 11h and 12k demonstrated synergistic action with Tpc on IMR-32 cell growth. 11h also enhanced
Tpc’s potency on HCT116 cells. These compounds show promise as candidates for anticancer therapy
in conjunction with Tpc.
2.2.3. Chemical Space
The calculated molecular descriptors MW (molecular weight), log P (water-octanol partition
coefficient), HD (hydrogen bond donors), HA (hydrogen bond acceptors), PSA (polar surface area),
and RB (rotatable bonds)) are given in Table S2. The molecular weight of the ligands lies between 206.3
and 327.3 g mol−1, falling into lead- and drug-like chemical spaces. The log P values range from 3.2
and 5.1, lying mostly in the drug-like but reaching into known drug space whilst the HD, HA, RB,
and PSA values are within the lead-like space (for the definition of lead-like, drug-like, and known
drug space (KDS) regions (see [41], Table S3).
The known drug index (KDI) of each ligand was calculated to gauge the balance of the molecular
descriptors of the ligands. This method is based on the statistical analysis of drugs in clinical use (KDS)
and a weighted index for each molecular descriptor. Both the summation (KDI2a) and multiplication
(KDI2b) methods were used [42]; as shown for KDI2a in Equation (1) and for KDI2b in Equation (2).
Finally, the numerical results are given in Table S4 in the Supplementary Material:
KDI2a = IMW + Ilog P + IHD+ IHA + IRB + IPSA, (1)
KDI2b = IMW × Ilog P × IHD× IHA × IRB × IPSA. (2)
The KDI2a values range from 4.15 to 5.15, with a theoretical maximum of 6 and an average of 4.08
for known drugs. KDI2b ranges from 0.10 to 0.39, with a theoretical maximum of 1 and with a KDS
average of 0.18. This indicates that the majority of the ligands are well balanced. 11h has KDI2a of
4.25 and KDI2b of 0.11 and 12g has similar values, with KDI2a of 4.16 and KDI2b of 0.10. The KDI2a of
both compounds is above the average index value for known drugs; however, the KDI2b is below the
average mainly due to the low PSA values. Nevertheless, these ligands can be considered reasonably
well balanced in terms of their molecular descriptors.
3. Materials and Methods
3.1. Chemistry
All commercially available compounds and solvents were reagent grade and used without
further treatment unless otherwise noted. We used montmorillonite K10 clay (Sigma-Aldrich, St. Louis,
MO, USA) as the catalyst. The clay was calcinated at 105 ◦C for 3 h immediately before use. CH2Cl2 was
passed through calcined Al2O3. The 2-carene-containing mixture was synthesized according to
Sidorenko et al. [31] by isomerization of 3-carene (Acros Organics, 98%). Column chromatography
(CC): silica gel (SiO2; 60–200 µ; Macherey-Nagel, Dueren, Germany); hexane/Et2O 100:0 → 90:10,
analysis of fractions composition after column chromatography: GC on an Agilent 7820A, HP-5 quartz
column, 30,000 × 0.25 mm, flame-ionization detector, He (1 atm) as the carrier gas. GC/MS (purity
control and products analysis): Agilent 7890A with a quadrupole mass spectrometer Agilent 5975C as
a detector, HP-5MS quartz column, 30,000 × 0.25 mm, He (1 atm) as the carrier gas. Optical rotation:
polAAr 3005 spectrometer, CHCl3 soln. HR-MS: DFS-Thermo-Scientific spectrometer in the full scan mode
(15–500 m/z, 70 eV electron-impact ionization, direct sample introduction). 1H and 13C NMR: Bruker
DRX-500 apparatus at 500.13 MHz (1H) and 125.76 MHz (13C) and Bruker Avance-III 600 apparatus
at 600.30 MHz (1H) and 150.95 MHz (13C) in CDCl3; chemical shifts δ in ppm rel. to residual CHCl3
(δ (H) 7.24, δ (C) 76.90 ppm), J in Hz; structure determinations by analyzing the 1H NMR spectra,
including 1H – 1H double resonance spectra and 1H – 1H 2D homonuclear correlation (COSY, NOESY);
J-modulated 13C NMR spectra (JMOD), and 13C – 1H 2D heteronuclear correlation with one-bond and
long-range spin-spin coupling constants (C – H COSY, 1J(C,H) = 135 Hz; HSQC, 1J(C,H) = 145 Hz;
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COLOC, 2,3J(C,H) = 10 Hz; HMBC, 2,3J(C,H) = 7 Hz). All the target compounds reported have a
purity of ≥95%. Numeration of atoms in the compounds (see Supplementary Material) is given for
assigning the signals in the NMR spectra and does not coincide with that for the names according to
the nomenclature of compounds. Spectral and analytical studies were carried out at the Collective
Chemical Service Center of the Siberian Branch of the Russian Academy of Sciences.
Numeration for the carbon atoms used for assignment in NMR spectra is presented in Figure 5
with compound (S)-11f and 12f as an example.
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3.1.1 General Procedure (GP) 
To the suspension of the K10 clay (3.0 g) in methylene chloride (15 mL) solution of 0.40 g 
aldehyde in methylene chloride (10 mL) and 1.0 g of a 2-carene containing mixture (10 wt.% of 2-
carene., 57 wt.% of the sum of 2- and 3-carenes, limonene, and menthadienes., obtained by 
isomerization of 3-carene according to [30,31], were added. The solvent was distilled off, and the 
reaction mixture was kept at rt for 20 h. Thereafter, ethyl acetate was added, the catalyst was filtered 
off, and the filtrate was evaporated. Isolation of the reaction products was carried out by column 
chromatography (silica gel (17 g), hexane/Et2O 100:0 → 90:10). Compounds 11 were eluted with a 4–
6% solution of Et2O in hexane, and compounds 12 and 13 with a 0.5–2% solution of Et2O in hexane. 
The yields of compounds 11, 12, and 13 were calculated based on the 2-carene content and on the 
sum of 2- and 3-carenes, limonene, and menthadienes, respectively. 
3.1.2 Reaction of 2-Carene-Containing Mixture and 4-hydroxy-3-methoxybenzaldehyde 10a. 
According to the GP, the reaction of the 2-carene containing mixture and 4-hydroxy-3-
methoxybenzaldehyde 10a gave isobenzofurans 11a (0.172 g, total yield 81%, (S)-/(R)- = 1:1), and 
compound 12a (0.135 g, 11%) was isolated. The spectrum of the substance (S)-11a, (R)-11a, and 12a 
corresponds to the literature [23]. 
3.1.3 Reaction of 2-Carene-Containing Mixture and Crotonaldehyde 10c. 
According to the GP, the reaction of the 2-carene containing mixture and crotonaldehyde 10c 
gave isobenzofurans 11c (0.135 g, total yield of 89%, (S)/(R) = 1.3: 1). The spectrum of the substance 
(S)-11c and (R)-10c corresponds to the literature [23]. 
3.1.4 Reaction of 2-Carene-Containing Mixture and 2-Thiophenecarbaldehyde 10d. 
According to the GP, the reaction of the 2-carene containing mixture and 2-
thiophenecarbaldehyde 10d gave (1S,3aR,7aS)-3,3,6-trimethyl-1-(thiophen-2-yl)-1,3,3a,4,5,7a-
hexahydroisobenzofuran 11d (0.143 g, 78 %) and the mixture of (1R,4R,5R)-2,2,6-trimethyl-4-
(thiophen-2-yl)-3-oxabicyclo[3.3.1]non-6-ene 12d and (1R,4R,5R)-2,2-dimethyl-6-methylene-4-
(thiophen-2-yl)-3-oxabicyclo[3.3.1]nonane 13d (0.050 g, 5 %, 7:1). 
11d: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.28 (s, 3H, Me-9), 1.39 (s, 3H, Me-8), 1.51-1.60 (m, 
1H, Ha-4), 1.68 (br.s, 3H, Me-10), 1.74 (dm, 1H, 2J = 13.0, He-4), 1.95-2.01 (m, 3H, 2H-5, H-3a), 2.83-2.88 
(m, 1H, H-7a), 4.85 (d, 1H, J1,7a = 10.0, H-1), 5.27-5.29 (m, 1H, H-7), 6.93 (dd, 1H, J13,14 = 5.0, J13,12 = 3.5, 
H-13), 6.96 (dm, 1H, J12,13 = 3.5, H-12), 7.22 (dd, 1H, J14,13 = 5.0, J14,12 = 1.2, H-14). NMR 13C (150 MHz, 
CDCl3, δ, ppm): 81.33 (d, C-1), 83.05 (c, C-3), 46.38 (d, C-3a), 21.83 (t, C-4), 29.98 (t, C-5), 136.55 (c, C-
6), 118.41 (d, C-7), 48.68 (d, C-7a), 30.92 (q, C-8), 24.00 (q, C-9), 23.49 (q, C-10), 146.76 (s, C-11), 123.89 
(d, C-12), 126.42 (d, C-13), 124.26 (d, C-14). HR-MS: m/z calcd. for C15H20OS: 248.1229. Found: 
248.1227.  = 120 (c = 0.3, CHCl3). 30D][ α
i r 5. u eration of carbon ato s f r s ctr .
3.1.1. General Procedure (GP)
To the suspension of the K10 clay (3.0 g) in methylene chloride (15 mL) solution of 0.40 g aldehyde
in methylene chloride (10 mL) and 1.0 g of a 2-carene containing mixture (10 wt.% of 2-carene., 57 wt.%
of the sum of 2- and 3-carenes, limonene, and menthadienes., obtained by isomerization of 3-carene
according to [30,31], were added. The solvent was distilled off, and the reaction mixture was kept
at rt for 20 h. Thereafter, ethyl acetate was added, the catalyst was filtered off, and the filtrate was
evaporated. Isolation of the reaction products was carried out by column chromatography (silica gel
(17 g), hexane/Et2O 100:0→ 90:10). Compounds 11 were eluted with a 4–6% solution of Et2O in hexane,
and compounds 12 and 13 with a 0.5–2% solution of Et2O in hexane. The yields of compounds 11, 12,
and 13 were calculated based on the 2-carene content and on the sum of 2- and 3-carenes, limonene,
and menthadienes, respectively.
3.1.2. Reaction of 2-Carene-Containing Mixture and 4-hydroxy-3-methoxybenzaldehyde 10a
According to the GP, the reaction of the 2-carene containing mixture and
4-hydroxy-3-methoxybenzaldehyde 10a gave isobenzofurans 11a (0.172 g, total yield 81%,
(S)-/(R)- = 1:1), and compound 12a (0.135 g, 11%) was isolated. The spectrum of the substance (S)-11a,
(R)-11a, and 12a corresponds to the literature [23].
3.1.3. Reaction of 2-Carene-Containing Mixture and Crotonaldehyde 10c
According to the GP, the reaction of the 2-carene containing mixture and crotonaldehyde 10c gave
isobenzofurans 11c (0.135 g, total yield of 89%, (S)/(R) = 1.3: 1). The spectrum of the substance (S)-11c
and (R)-10c corresponds to the literature [23].
3.1.4. Reaction of 2-Carene-Containing Mixture and 2-Thiophenecarbaldehyde 10d
According to the GP, the reaction of the 2-carene containing mixture and 2-thiophenecarbaldehyde
10d gave (1S,3aR,7aS)-3,3,6-trimethyl-1-(thiophen-2-yl)-1,3,3a,4,5,7a-hexahydroisobenzofuran 11d
(0.143 g, 78%) and the mixture of (1R,4R,5R)-2,2,6-trimethyl-4-(thiophen-2-yl)-3-oxabicyclo[3.3.1]non-
6-ene 12d and (1R,4R,5R)-2,2-dimethyl-6-methylene-4-(thiophen-2-yl)-3-oxabicyclo[3.3.1]nonane 13d
(0.050 g, 5%, 7:1).
11d: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.28 (s, 3H, Me-9), 1.39 (s, 3H, Me-8), 1.51–1.60 (m,
1H, Ha-4), 1.68 (br.s, 3H, Me-10), 1.74 (dm, 1H, 2J = 13.0, He-4), 1.95–2.01 (m, 3H, 2H-5, H-3a), 2.83–2.88
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(m, 1H, H-7a), 4.85 (d, 1H, J1,7a = 10.0, H-1), 5.27–5.29 (m, 1H, H-7), 6.93 (dd, 1H, J13,14 = 5.0, J13,12 = 3.5,
H-13), 6.96 (dm, 1H, J12,13 = 3.5, H-12), 7.22 (dd, 1H, J14,13 = 5.0, J14,12 = 1.2, H-14). NMR 13C (150 MHz,
CDCl3, δ, ppm): 81.33 (d, C-1), 83.05 (c, C-3), 46.38 (d, C-3a), 21.83 (t, C-4), 29.98 (t, C-5), 136.55 (c, C-6),
118.41 (d, C-7), 48.68 (d, C-7a), 30.92 (q, C-8), 24.00 (q, C-9), 23.49 (q, C-10), 146.76 (s, C-11), 123.89
(d, C-12), 126.42 (d, C-13), 124.26 (d, C-14). HR-MS: m/z calcd. for C15H20OS: 248.1229. Found:
248.1227. [α]30D = 120 (c = 0.3, CHCl3).
The NMR spectra of 12d and 13d were recorded for their mixture (≈ 7:1).
12d: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.00–1.03 (m, 3H, Me-12), 1.30 (s, 3H, Me-10),
1.37 (s, 3H, Me-11), 1.51–1.56 (m, 1H, H-1), 1.71 (ddd, 1H, 2J = 12.5, J9an,1 = J9an,5 = 3.2, H-9an),
2.08 (dm, 1H, J8k,8n = 18.8, H-8k), 2.21 (ddd, 1H, J5,9s = J5,9an = 3.2, J5,4 = 2.3, H-5), 2.30 (dddd, 1H,
2J = 12.5, J9s,1 = J9s,5 = 3.2, J9s,8n = 1.2, H-9s), 2.38 (br.d, 1H, 2J = 18.8, H-8n), 5.14 (d, 1H, J4,5 = 2.3,
H-4), 5.46–5.49 (m, 1H, H-7), 6.89 (dm, 1H, J14,15 = 3.5, H-14), 6.91 (dd, 1H, J15,16 = 5.0, J15,14 = 3.5,
H-15), 7.12 (dd, 1H, J16,15 = 5.0, J16,14 = 1.3, H-16). NMR 13C (150 MHz, CDCl3, δ, ppm): 33.86 (d, C-1),
75.89 (c, C-2), 71.94 (d, C-4), 42.31 (d, C-5), 133.04 (c, C-6), 123.46 (d, C-7), 27.55 (t, C-8), 27.74 (t, C-9),
28.44 (q, C-10), 23.87 (q, C-11), 23.97 (q, C-12), 146.97 (c, C-13), 121.54 (d, C-14), 126.04 (d, C-15), 123.05
(d, C-16). HR-MS: m/z calcd. for C15H20OS: 248.1229. Found: 248.1230.
13d: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.36 (s, 3H, Me-10), 1.40 (s, 3H, Me-11), 1.50–1.53
(m, 1H, H-1), 1.72–1.77 (m, 1H, H-9s), 2.86–2.93 (m, 1H, Ha-7), 4.31 (dd, 1H, 2J = 2.3, J12,5 = 2.3, H-12),
4.56 (dd, 1H, 2J = 2.3, J12′,5 = 2.3, H-12′), 5.22 (br.d, 1H, J4,5 = 1.9, H-4), 6.87 (dm, 1H, J14,15 = 3.5, H-14),
7.07–7.10 (m, 1H, H-15), 7.11–7.13 (m, 1H, H-16). The remaining proton signals are overlapped by the
signals of the main isomer 12a. NMR 13C (150 MHz, CDCl3, δ, ppm): 35.10 (d, C-1), 75.99 (c, C-2), 73.46
(d, C-4), 46.00 (d, C-5), 148.29 (c, C-6), 31.08 (t, C-7), 28.92 (t, C-8), 32.05 (t, C-9), 27.85 (q, C-10), 24.29
(q, C-11), 109.69 (t, C-12), 148.29 (c, C-13), 122.40 (d, C-14), 125.66 (d, C-15), 129.45 (d, C-16). HR-MS:
m/z calcd. for C15H20OS: 248.1229. Found: 248.1230.
3.1.5. Reaction of 2-Carene-Containing Mixture and 3-methylthiophene-2-carbaldehyde 10e
According to the GP, the reaction of the 2-carene-containing mixture and 3-methylthiophene
-2-carbaldehyde 10e gave (1S,3aR,7aS)-3,3,6-trimethyl-1-(3-methylthiophen-2-yl)-1,3,3a,4,5,
7a-hexahydroisobenzofuran 11e (0.167 g, 86%) and (1R,4R,5R)-2,2,6-trimethyl-4-(3-methylthiophen-2-yl)
-3-oxabicyclo[3.3.1]non-6-ene 12e (0.025 g, 2%).
11e: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.28 (s, 3H, Me-9), 1.41 (s, 3H, Me-8), 1.57–1.65
(m, 1H, Ha-4), 1.67 (br.s, 3H, Me-10), 1.74 (dm, 1H, 2J = 12.9, He-4), 1.96–2.02 (m, 3H, 2H-5, H-3a), 2.17
(s, 3H, Me-15), 2.84–2.90 (m, 1H, H-7a), 4.92 (d, 1H, J1,7a = 10.1, H-1), 5.21–5.24 (m, 1H, H-7), 6.74 (d, 1H,
J13,14 = 5.0, H-13), 7.13 (d, 1H, J14,13 = 5.0, H-14).
NMR 13C (150 MHz, CDCl3, δ, ppm): 79.14 (d, C-1), 82.64 (c, C-3), 46.40 (d, C-3a), 21.92 (t, C-4),
30.02 (t, C-5), 136.38 (c, C-6), 118.47 (d, C-7), 49.18 (d, C-7a), 31.14 (q, C-8), 24.03 (q, C-9), 23.45 (q, C-10),
139.46 (s, C-11), 134.13 (s, C-12), 129.79 (d, C-13), 123.04 (d, C-14), 13.88 (q, C-15). HR-MS: m/z calcd.
for C16H22OS: 262.1386. Found: 262.1388. [α]
30
D = 100 (c = 0.6, CHCl3).
12e: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 0.97–1.00 (m, 3H, Me-12), 1.29 (s, 3H, Me-10), 1.37
(s, 3H, Me-11), 1.51–1.55 (m, 1H, H-1), 1.70 (ddd, 1H, 2J = 12.5, J9an,1 = J9an,5 = 3.1, H-9an), 2.04–2.09
(m, 1H, H-8k), 2.20 (s, 3H, Me-17), 2.20–2.22 (m, 1H, H-5), 2.28 (dddd, 1H, 2J = 12.5, J9s,1 = J9s,5 = 3.1,
J9s,8n = 1.2, H-9s), 2.39 (br.d, 1H, 2J = 18.4, H-8n), 5.10 (d, 1H, J4,5 = 2.5, H-4), 5.46–5.49 (m, 1H, H-7),
6.71 (d, 1H, J15,16 = 5.0, H-15), 7.04 (d, 1H, J16,15 = 5.0, H-16).
NMR 13C (150 MHz, CDCl3, δ, ppm): 33.79 (d, C-1), 75.79 (c, C-2), 71.15 (d, C-4), 39.12 (d, C-5),
133.11 (c, C-6), 123.51 (d, C-7), 27.44 and 27.49 (2t, C-8, C-9), 28.47 (q, C-10), 23.89 (q, C-11), 23.61
(q, C-12), 140.20 (c, C-13), 129.93 (s, C-14), 129.03 (d, C-15), 122.72 (d, C-16), 14.09 (q, C-17). HR-MS:
m/z calcd. for C16H22OS: 262.1386. Found: 262.1384. [α]
30
D = 0 (c = 0.3, CHCl3).
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3.1.6. Reaction of 2-Carene-Containing Mixture and 5-methylthiophene-2-carbaldehyde 10f
According to the GP, the reaction of the 2-carene-containing mixture and 5-methylthiophene
-2-carbaldehyde 10f gave (1S,3aR,7aS)-3,3,6-trimethyl-1-(5-methylthiophen-2-yl)-1,3,3a,4,5,7a-
hexahydroisobenzofuran 11f (0.163 g, 85%) and mixture of (1R,4R,5R)-2,2,6-trimethyl-
4-(5-methylthiophen-2-yl)-3-oxabicyclo[3.3.1]non-6-ene 12f and (1R,4R,5R)-2,2-dimethyl-6-methylene-
4-(5-methylthiophen-2-yl)-3-oxabicyclo[3.3.1]nonane 13f (0.025 g, 2%, 3:1).
11f: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.27 (s, 3H, Me-9), 1.38 (s, 3H, Me-8), 1.51–1.59
(m, 1H, Ha-4), 1.68 (br.s, 3H, Me-10), 1.73 (dm, 1H, 2J = 12.9, He-4), 1.94–2.01 (m, 3H, 2H-5, H-3a), 2.44
(d, 3H, J15,13 = 0.8, Me-15), 2.82–2.87 (m, 1H, H-7a), 4.75 (d, 1H, J1,7a = 10.0, H-1), 5.27–5.30 (m, 1H, H-7),
6.56 (dq, 1H, J13,12 = 3.5, J13,15 = 0.8, H-13), 6.74 (d, 1H, J12,13 = 3.5, H-12). NMR 13C (150 MHz, CDCl3,
δ, ppm): 81.45 (d, C-1), 82.78 (c, C-3), 46.31 (d, C-3a), 21.81 (t, C-4), 29.97 (t, C-5), 136.34 (c, C-6), 118.54
(d, C-7), 48.41 (d, C-7a), 30.92 (q, C-8), 23.98 (q, C-9), 23.45 (q, C-10), 144.02 (s, C-11), 124.15 (d, C-12),
124.38 (d, C-13), 138.92 (s, C-14), 15.29 (q, C-15). HR-MS: m/z calcd. for C16H22OS: 262.1386. Found:
262.1382. [α]30D = 119 (c = 0.4, CHCl3).
The NMR spectra of 12f and 13f were recorded for their mixture (≈ 3:1).
12f: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.10–1.12 (m, 3H, Me-12), 1.28 (s, 3H, Me-10),
1.35 (s, 3H, Me-11), 1.50–1.53 (m, 1H, H-1), 1.69 (ddd, 1H, 2J = 12.5, J9an,1 = J9an,5 = 3.2, H-9an), 2.06
(dm, 1H, J8k,8n = 18.8, H-8k), 2.17 (ddd, 1H, J5,9s = J5,9an = 3.2, J5,4 = 2.0, H-5), 2.27 (dddd, 1H, 2J = 12.5,
J9s,1 = J9s,5 = 3.2, J9s,8n = 1.2, H-9s), 2.36 (br.d, 1H, 2J = 18.8, H-8n), 2.39 (br.s, 3H, Me-17), 5.04 (br.d, 1H,
J4,5 = 2.0, H-4), 5.45–5.48 (m, 1H, H-7), 6.53–6.55 (m, 1H, H-15), 6.65 (dd, 1H, J14,15 = 3.3, J14,4 = 1.0,
H-14). NMR 13C (150 MHz, CDCl3, δ, ppm): 33.87 (d, C-1), 75.78 (c, C-2), 71.93 (d, C-4), 42.22 (d, C-5),
133.29 (c, C-6), 123.28 (d, C-7), 27.56 (t, C-8), 27.74 (t, C-9), 28.46 (q, C-10), 23.87 (q, C-11), 24.20 (q, C-12),
144.32 (c, C-13), 121.31 (d, C-14), 124.03 (d, C-15), 137.35 (s, C-16), 15.06 (q, C-17). HR-MS: m/z calcd. for
C16H22OS: 262.1386. Found: 262.1387. [α]
30
D = 0 (c = 0.2, CHCl3).
13f: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.33 (s, 3H, Me-10), 1.38 (s, 3H, Me-11), 1.47–1.50
(m, 1H, H-1), 2.09–2.16 (m, 2H, H-7e, H-8e), 2.36–2.46 (m, 2H, H-9an, H-5), 2.39 (br.s, 3H, Me-17),
2.86–2.93 (m, 1H, Ha-7), 4.37 (dd, 1H, 2J = 2.4, J12,5 = 2.4, H-12), 4.61 (dd, 1H, 2J = 2.4, J12′,5 = 2.4,
H-12′), 5.11 (br.d, 1H, J4,5 = 1.9, H-4), 6.53–6.55 (m, 1H, H-15), 6.65 (dd, 1H, J14,15 = 3.3, J14,4 = 1.0,
H-14). The remaining proton signals are overlapped by the signals of the main isomer 12f. NMR 13C
(150 MHz, CDCl3, δ, ppm): 35.12 (d, C-1), 75.88 (c, C-2), 73.52 (d, C-4), 45.79 (d, C-5), 148.56 (c, C-6),
31.17 (t, C-7), 29.02 (t, C-8), 32.21 (t, C-9), 27.88 (q, C-10), 24.28 (q, C-11), 109.72 (t, C-12), 143.30 (c, C-13),
122.50 (d, C-14), 123.98 (d, C-15), 137.68 (s, C-16), 15.12 (q, C-17). HR-MS: m/z calcd. for C16H22OS:
262.1386. Found: 262.1387.
3.1.7. Reaction of 2-Carene-Containing Mixture and 4-bromothiophene-2-carbaldehyde 10g
According to the GP, the reaction of the 2-carene-containing mixture and 4-bromothiophene-
2-carbaldehyde 10g gave (1R,4R,5R)-2,2,6-trimethyl-4-(4-bromothiophen-2-yl)-3-oxabicyclo[3.3.1]non-
6-ene 12g (0.273 g, 20%).
12g: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.06–1.08 (m, 3H, Me-12), 1.28 (s, 3H, Me-10), 1.34
(s, 3H, Me-11), 1.50–1.54 (m, 1H, H-1), 1.70 (ddd, 1H, 2J = 12.5, J9an,1 = J9an,5 = 3.2, H-9an), 2.06 (dm, 1H,
2J = 18.8, H-8k), 2.16–2.19 (m, 1H, H-5), 2.27 (dm, 1H, 2J = 12.5, H-9s), 2.35 (br.d, 1H, 2J = 18.8, H-8n),
5.05 (dd, 1H, J4,5 = 2.5, J4,14 = 0.7, H-4), 5.46–5.49 (m, 1H, H-7), 6.81 (dd, 1H, J14,16 = 1.5, J14,4 = 0.7, H-14),
7.03 (d, 1H, J16,14 = 1.5, H-16). NMR 13C (150 MHz, CDCl3, δ, ppm): 33.73 (d, C-1), 76.18 (c, C-2), 71.49
(d, C-4), 42.10 (d, C-5), 132.46 (c, C-6), 123.93 (d, C-7), 27.49 and 27.62 (2t, C-8, C-9), 28.33 (q, C-10), 23.85
(q, C-11), 24.12 (q, C-12), 148.37 (c, C-13), 124.37 (d, C-14), 108.51 (s, C-15), 120.68 (d, C-16). HR-MS:
m/z calcd. for C15H19OBrS: 326.0335. Found: 326.0334. [α]
30
D = 0 (c = 1.3, CHCl3).
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3.1.8. Reaction of 2-Carene-Containing Mixture and 5-bromothiophene-2-carbaldehyde 10h
According to the GP, the reaction of the 2-carene-containing mixture and 5-bromothiophene
-2-carbaldehyde 10h gave (1S,3aR,7aS)-3,3,6-trimethyl-1-(5-bromothiophen-2-yl)-1,3,3a,4,5,7a-
hexahydroisobenzofuran 11h (0.176 g, 73%) and (1R,4R,5R)-2,2,6-trimethyl-4-(5-bromothiophen-2-yl)-3-
oxabicyclo[3.3.1]non-6-ene 12h (0.199 g, 15%).
11h: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.26 (s, 3H, Me-9), 1.36 (s, 3H, Me-8), 1.47–1.56
(m, 1H, Ha-4), 1.68 (br.s, 3H, Me-10), 1.72 (dm, 1H, 2J = 12.9, He-4), 1.93–2.00 (m, 3H, 2H-5, H-3a),
2.75–2.81 (m, 1H, H-7a), 4.74 (d, 1H, J1,7a = 9.9, H-1), 5.24–5.27 (m, 1H, H-7), 6.69 (dd, 1H, J12,13 = 3.7,
J12,3a = 0.8, H-12), 6.86 (d, 1H, J13,12 = 3.7, H-13). NMR 13C (150 MHz, CDCl3, δ, ppm): 81.56 (d, C-1),
83.42 (c, C-3), 46.27 (d, C-3a), 21.73 (t, C-4), 29.92 (t, C-5), 136.95 (c, C-6), 117.95 (d, C-7), 48.56 (d, C-7a),
30.83 (q, C-8), 23.92 (q, C-9), 23.49 (q, C-10), 148.65 (s, C-11), 124.00 (d, C-12), 129.22 (d, C-13), 110.99
(s, C-14). HR-MS: m/z calcd. for C15H19OBrS: 326.0335. Found: 326.0330. [α]
30
D = 34 (c = 1.2, CHCl3).
12h: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.10–1.12 (m, 3H, Me-12), 1.27 (s, 3H, Me-10), 1.34
(s, 3H, Me-11), 1.50–1.54 (m, 1H, H-1), 1.69 (ddd, 1H, 2J = 12.5, J9an,1 = J9an,5 = 3.2, H-9an), 2.06 (dm,
1H, J8k,8n = 18.8, H-8k), 2.15–2.18 (m, 1H, H-5), 2.26 (dddd, 1H, 2J = 12.5, J9s,1 = J9s,5 = 3.2, J9s,8n = 1.1,
H-9s), 2.35 (br.d, 1H, 2J = 18.8, H-8n), 5.03 (br.d, 1H, J4,5 = 2.1, H-4), 5.47–5.50 (m, 1H, H-7), 6.63 (dd,
1H, J14,15 = 3.7, J14,4 = 0.8, H-14), 6.85 (d, 1H, J15,14 = 3.7, H-15). NMR 13C (150 MHz, CDCl3, δ, ppm):
33.74 (d, C-1), 76.09 (c, C-2), 72.07 (d, C-4), 42.00 (d, C-5), 132.61 (c, C-6), 123.87 (d, C-7), 27.49 (t, C-8),
27.55 (t, C-9), 28.35 (q, C-10), 23.84 (q, C-11), 24.24 (q, C-12), 148.84 (c, C-13), 121.61 (d, C-14), 128.76
(d, C-15), 109.96 (s, C-16). HR-MS: m/z calcd. for C15H19OBrS: 326.0335. Found: 326.0331. [α]
30
D = 0
(c = 0.9, CHCl3).
3.1.9. Reaction of 2-Carene-Containing Mixture and 5-nitrothiophene-2-carbaldehyde 10i
According to the GP, the reaction of the 2-carene-containing mixture and 5-nitrothiophene- 2-carbaldehyde
10i gave a mixture of (1R,4R,5R)-2,2,6-trimethyl-4-(5-methylthiophen-2-yl)-3-oxabicyclo[3.3.1]non-6-ene
12i and (1R,4R,5R)-2,2-dimethyl-6-methylene-4-(5-methylthiophen-2-yl)-3-oxabicyclo[3.3.1]nonane 13i
(0.221 g, 18%, 5.4:1).
The NMR spectra of 12i and 13i were recorded for their mixture (≈ 5.4:1).
12i: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.03–1.05 (m, 3H, Me-12), 1.27 (s, 3H, Me-10),
1.338 (s, 3H, Me-11), 1.53–1.56 (m, 1H, H-1), 1.73 (ddd, 1H, 2J = 12.5, J9an,1 = J9an,5 = 3.2, H-9an), 2.07
(dm, 1H, 2J = 19.0, H-8k), 2.23–2.26 (m, 1H, H-5), 2.28 (dddd, 1H, 2J = 12.5, J9s,1 = J9s,5 = 3.2, J9s,8n = 1.2,
H-9s), 2.35 (br.d, 1H, 2J = 19.0, H-8n), 5.06 (br.d, 1H, J4,5 = 2.4, H-4), 5.48–5.51 (m, 1H, H-7), 6.84 (dd,
1H, J14,15 = 4.2, J14,4 = 1.0, H-14), 7.75 (d, 1H, J15,14 = 4.2, H-15). NMR 13C (150 MHz, CDCl3, δ, ppm):
33.49 (d, C-1), 76.60 (c, C-2), 71.74 (d, C-4), 41.75 (d, C-5), 131.38 (c, C-6), 124.82 (d, C-7), 27.35 (t, C-8),
27.45 (t, C-9), 28.14 (q, C-10), 23.77 (q, C-11), 24.12 (q, C-12), 157.31 (c, C-13), 120.69 (d, C-14), 128.02 (d,
C-15), 150.16 (br.s, C-16). HR-MS: m/z calcd. for C15H19O3NS: 293.1080. Found: 293.1076.
13i: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.342 (s, 3H, Me-10), 1.37 (s, 3H, Me-11), 1.47–1.53
(m, 1H, H-8a), 1.76 (dm, 1H, 2J = 13.0, H-9s), 2.07–2.12 (m, 2H, H-7e, H-8e), 2.36–2.41 (m, 1H, H-9a),
2.43–2.46 (m, 1H, H-5), 2.67–2.75 (m, 1H, H-7a), 4.30 (dd, 1H, 2J = 2.4, J12,5 = 2.4, H-12), 4.54 (dd, 1H,
2J = 2.4, J12′,5 = 2.4, H-12′), 5.16 (br.d, 1H, J4,5 = 2.5, H-4), 6.73 (dd, 1H, J14,15 = 4.2, J14,4 = 1.0, H-14),
7.75 (d, 1H, J15,14 = 4.2, H-15). The H-1 signal is overlapped by the H-1 signal of the main isomer 12i.
NMR 13C (150 MHz, CDCl3, δ, ppm): 34.76 (d, C-1), 76.71 (c, C-2), 73.30 (d, C-4), 45.30 (d, C-5), 146.62
(c, C-6), 30.73 (t, C-7), 28.46 (t, C-8), 31.39 (t, C-9), 27.53 (q, C-10), 24.23 (q, C-11), 110.58 (q, C-12), 156.23
(c, C-13), 121.10 (d, C-14), 128.22 (d, C-15), ≈150 (br.s, C-16). Broad singlet signal of C-16 could not be
determined accurately due to low concentrations of 13i. HR-MS: m/z calcd. for C15H19O3NS: 293.1080.
Found: 293.1076.
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3.1.10. Reaction of 2-Carene-Containing Mixture and 5-nitrofuran-2-carbaldehyde 10j
According to the GP, the reaction of the 2-carene-containing mixture and 5-nitrofuran-
2-carbaldehyde 10j gave (1R,4R,5R)-2,2,6-trimethyl-4-(5-nitrofuran-2-yl)-3-oxabicyclo[3.3.1]non-6-ene
12j (0.215 g, 18%).
12j: NMR 1H (600 MHz, CDCl3, δ, ppm, J/Hz): 1.08–1.09 (m, 3H, all J < 2.5 Hz, Me-12), 1.28 (s,
3H, Me-10), 1.35 (s, 3H, Me-11), 1.54–1.58 (m, 1H, H-1), 1.75 (ddd, 1H, 2J = 12.6, J9an,1 = J9an,5 = 3.2,
H-9an), 2.09 (dm, 1H, J8k,8n = 18.9, H-8k), 2.25 (dm, 1H, 2J = 12.6, H-9s), 2.34 (dm, 1H, 2J = 18.9, H-8n),
2.46–2.49 (m, 1H, H-5), 4.90 (br.d, 1H, J4,5 = 2.2, H-4), 5.48–5.51 (m, 1H, H-7), 6.39 (dd, 1H, J14,15 = 3.7,
J14,4 = 1.2, H-14), 7.24 (d, 1H, J15,14 = 3.7, H-15). NMR 13C (150 MHz, CDCl3, δ, ppm): 33.75 (d, C-1),
76.38 (c, C-2), 69.63 (d, C-4), 38.69 (d, C-5), 131.49 (c, C-6), 124.56 (d, C-7), 27.47 (t, C-8), 27.00 (t, C-9),
28.23 (q, C-10), 23.65 (q, C-11), 23.07 (q, C-12), 160.14 (c, C-13), 108.81 (d, C-14), 112.97 (d, C-15), 150.96
(s, C-16). HR-MS: m/z calcd. for C15H19O4N: 277.1309. Found: 277.1306.
3.1.11. Reaction of 2-Carene-Containing Mixture and thiophene-3-carbaldehyde 10k
According to the GP, the reaction of the 2-carene-containing mixture and thiophene-3-carbaldehyde
10k gave (1S(R),3aR,7aS)-3,3,6-trimethyl-1-(thiophen-3-yl)-1,3,3a,4,5,7a-hexahydroisobenzofuran 11k
(0.165 g, 91%, S/R = 1.5:1) and (1R,4R,5R)-2,2,6-trimethyl-4-(thiophen-3-yl)-3-oxabicyclo[3.3.1]non-6-ene
12k (0.213 g, 21%).
The NMR spectra of compound 11k were recorded for the mixture (S)-11k and (R)-11k isomers
(1.3:1).
(S)-11k: NMR 1H (500 MHz, CDCl3, δ, ppm, J/Hz): 1.28 (s, 3H, Me-9), 1.37 (s, 3H, Me-8), 1.53–1.61
(m, 1H, Ha-4), 1.68 (br.s, 3H, Me-10), 1.69–1.76 (m, 1H, He-4), 1.88–2.02 (m, 3H, 2H-5, H-3a), 2.73–2.80
(m, 1H, H-7a), 4.68 (d, 1H, J1,7a = 10.1, H-1), 5.22–5.25 (m, 1H, H-7), 7.09 (dd, 1H, J12,13 = 5.0, J12,14 = 1.3,
H-12), 7.18 (ddd, 1H, J14,13 = 3.0, J14,13 = 1.3, J14,1 = 0.7, H-14), 7.22 (dd, 1H, J13,12 = 5.0, J13,14 = 3.0,
H-13). NMR 13C (125 MHz, CDCl3, δ, ppm): 81.53 (d, C-1), 82.61 (c, C-3), 46.20 (d, C-3a), 21.82 (t, C-4),
29.99 (t, C-5), 136.40 (c, C-6), 118.65 (d, C-7), 47.37 (d, C-7a), 30.95 (q, C-8), 24.02 (q, C-9), 23.53 (q, C-10),
143.91 (s, C-11), 125.64 (d, C-12), 125.68 (d, C-13), 120.75 (d, C-14). HR-MS: m/z calcd. for C15H20OS:
248.1229. Found: 248.1230.
(R)-11k: NMR 1H (500 MHz, CDCl3, δ, ppm, J/Hz): 1.30 (s, 3H, Me-8), 1.33 (s, 3H, Me-9), 1.50 (br.s,
3H, Me-10), 1.69–1.76 (m, 1H, He-4), 1.81–1.85 (m, 2H, 2H-5), 1.89–1.97 (m, 1H, H-3a), 3.17–3.24 (m,
1H, H-7a), 4.89–4.93 (m, 1H, H-7), 5.22 (d, 1H, J1,7a = 9.5, H-1), 6.89 (dd, 1H, J12,13 = 5.0, J12,14 = 1.2,
H-12), 7.08 (dm, 1H, J14,13 = 3.0, H-14), 7.17 (dd, 1H, J13,12 = 5.0, J13,14 = 3.0, H-13). NMR 13C (125 MHz,
CDCl3, δ, ppm): 77.91 (d, C-1), 81.72 (c, C-3), 44.94 (d, C-3a), 22.45 (t, C-4), 28.70 (t, C-5), 134.35 (c, C-6),
119.72 (d, C-7), 42.83 (d, C-7a), 26.98 (q, C-8), 23.76 (q, C-9), 23.49 (q, C-10), 142.92 (s, C-11), 126.92 (d,
C-12), 124.49 (d, C-13), 121.07 (d, C-14). HR-MS: m/z calcd. for C15H20OS: 248.1229. Found: 248.1230.
12k: NMR 1H (500 MHz, CDCl3, δ, ppm, J/Hz): 0.95–0.98 (ddd, 3H, J12,7 = 2.4, J12,8k = 2.1,
J12,8n = 1.8, Me-12), 1.29 (s, 3H, Me-10), 1.36 (s, 3H, Me-11), 1.52–1.55 (m, 1H, H-1), 1.71 (ddd, 1H,
2J = 12.5, J9an,1 = J9an,5 = 3.2, H-9an), 2.07 (dm, 1H, J8k,8n = 18.8, H-8k), 2.17–2.19 (m, 1H, H-5), 2.30
(dddd, 1H, 2J = 12.5, J9s,1 = J9s,5 = 3.2, J9s,8n = 1.2, H-9s), 2.37 (br.d, 1H, 2J = 18.8, H-8n), 4.95 (d, 1H,
J4,5 = 2.1, H-4), 5.42–5.45 (m, 1H, H-7), 6.98 (dd, 1H, J14,15 = 5.0, J14,16 = 1.2, H-14), 7.09 (ddd, 1H,
J16,15 = 3.0, J16,14 = 1.2, J16,4 = 0.8, H-16), 7.19 (dd, 1H, J15,14 = 5.0, J15,16 = 3.0, H-15). NMR 13C (125 MHz,
CDCl3, δ, ppm): 33.97 (d, C-1), 75.31 (c, C-2), 72.06 (d, C-4), 40.97 (d, C-5), 133.23 (c, C-6), 123.14 (d, C-7),
27.61 (t, C-8), 27.92 (t, C-9), 28.58 (q, C-10), 23.87 (q, C-11), 23.68 (q, C-12), 144.27 (c, C-13), 125.62 (d,
C-14), 119.47 (d, C-15), 124.69 (d, C-16). HR-MS: m/z calcd. for C15H20OS: 248.1229. Found: 248.1230.
[α]30D = 0 (c = 1.8, CHCl3).
3.1.12. Reaction of Limonene and 2-thiophenecarbaldehyde 10d
To the suspension of the K10 (1.5 g) in methylene chloride (15 mL), a solution of 0.40 g aldehyde
in methylene chloride (5 mL) and 0.50 g of limonene was added. The solvent was distilled off, and the
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reaction mixture was kept at room temperature for 2 h. Thereafter, ethyl acetate was added, the catalyst
was filtered off, and the filtrate was evaporated. Isolation of the reaction products was carried out by
column chromatography to give 11d and 12d (0.582 g, 64%, 14:1).
3.2. Real-Time Detection of TDP1 Activity
A fluorophore quencher-coupled oligonucleotide biosensor was used for TDP1 enzyme activity
real-time fluorescence detection [38]. The biosensor 5′-FAM-AAC GTC AGG GTC TTC C- BHQ1-3′ is
a 16-mer single-stranded oligonucleotide with a 5′- fluorophore (FAM), and a 3′-quencher (BHQ1).
Recombinant protein TDP1 was expressed in Escherichia coli (pET 16B plasmid containing TDP1 cDNA
was provided by Dr. K.W. Caldecott, University of Sussex, United Kingdom) and isolated as described
by Lebedeva et al. [43]. The reaction mixture contained TDP1 reaction buffer (50 mM Tris-HCl, 50 mM
NaCl, 7 mM β-mercaptoethanol), 50 nM oligonucleotide substrate, varied concentrations of the tested
compounds, and 1.5 nM purified TDP1 in a final volume of 200 µL.
The TDP1 reaction mixture was incubated at rt in a POLARstar OPTIMA fluorimeter
(BMG LABTECH, GmbH). Fluorescence intensity was measured every 1 min (Ex485/Em520 nm).
The efficiency of TDP1 inhibition was evaluated by comparing the rate of increase in the fluorescence
of the biosensor in the presence of the compound to that of DMSO (1.5%) control wells. IC50 values
were determined using an 11-point concentration–response curve. The data were imported into MARS
Data Analysis 2.0 program (BMG LABTECH) and the slope during the linear phase was calculated.
The IC50 measurements were carried out in at least three independent experiments.
3.3. TDP1 Activity by Gel-Based Assay
A fluorophore-labeled oligonucleotide 5′- FAM-AAC GTC AGG GTC TTC C-tyrosine-3′ was
used as a standard gel-based method for the indication of TDP1 enzyme activity. The oligonucleotide
containing a natural phosphotyrosine adduct at the 3′-end is a substrate for TDP1 [33]. The reaction
mixture contained reaction buffer (50 mM Tris-HCl, 50 mM NaCl, 7 mM β-mercaptoethanol), 50 nM
oligonucleotide substrate, 5 nM purified TDP1, or 1 µg of cell extract in a final volume of 20 µL.
The reaction was conducted at 37 ◦C for 20 min. The reaction products were separated by electrophoresis
in a 20% denaturing polyacrylamide gel with 7 M urea. A Typhoon FLA 9500 phosphorimager
(GE Healthcare) was used for gel scanning and imaging, and the data were analyzed with QuantityOne
4.6.7 software.
3.4. Obtainment of TDP1 Knockout HEK293FT Clones
3.4.1. Plasmid Construction for Human TDP1 Gene Knockout
The sgRNAs design was performed using the Benchling CRISPR tool (https://www.benchling.
com/). Two protospacers (PAM sequences in brackets) were selected for the DNA sequence
deletion in the first protein-coding exon of the human TDP1 gene exon 3 (third exon in
mRNA, NM_001008744.2): TDP1-gRNA1 AGACGAGTATGAGACATCAG(GGG) and TDP1-gRNA2
GCAGAAAAGCGGTTCCCAGG(AGG). Corresponding oligonucleotides were cloned in plasmid
pSpCas9(BB)-2A-GFP (PX458) (the plasmid was a gift from Feng Zhang (Addgene plasmid #48138;
http://n2t.net/addgene:48138; RRID:Addgene_48138)) as previously described [44]. Transfection-grade
plasmid DNA was isolated using the PureLink HiPure Plasmid Miniprep Kit (ThermoFisher Scientific,
Waltham, MA, USA).
3.4.2. Knockout HEK293FT Clone Generation
First, 5 × 105 HEK293FT cells were plated into a well of a 12-well plate and cotransfected with the
constructed plasmids TDP1-gRNA1 and TDP1-gRNA2 (0.25 µg of each) using Lipofectamine 3000
Reagent (Thermofisher Scientific). Growth medium contained DMEM/F12 (Gibco, Co Dublin, Ireland)
1:1, 10% fetal bovine serum (FBS) (Gibco), 100 U/mL penicillin-streptomycin (Gibco), and 1x GlutaMAX
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(Gibco). Then, 48 h after transfection, cells were detached using TrypLE Express (TrypLE, Gibco),
and the GFP-positive cell population was enriched by cell sorting using a BD FACSAria III Cell Sorter
(BD Biosciences, East Rutherford, NJ, USA). Transfected cells were plated onto a 96-well plate, one cell
per well. Single-cell clones grew for two weeks before they were replicated to another 96-well plate,
so we obtained two equal 96-well plates with cell clones: One plate was used for PCR analysis of the
deletion in the TDP1 gene while the other plate was used for the mutant cell clone multiplicatioin.
3.4.3. Analysis of CRISPR/Cas9-Mediated Deletions in the TDP1 Gene
Genome DNA was extracted from cells on one of two 96-well plates using 50 µL of QuickExtract™
DNA Extraction Solution (Epicentre) per well. The DNA extracts were diluted with 200 µL of
mQ water. Two microliters of diluted DNA extract were used for PCR amplification of the
target region with the primers: TDP1-scF 5′-TCAGGAAGGCGATTATGGGAG-3′ and TDP1-scR
5′-TTGATGTGGAGGGCTCCAG-3′. Reactions were run on a S1000 Thermal Cycler (Bio-Rad, Hercules,
CA ,USA) using BioMaster HS-Taq PCR-Color (2×) (Biolabmix, Novosibirsk Oblast, Russia) with the
following program: 95 ◦C 3 min; 35 cycles: 95 ◦C 30 s, 68 ◦C 30 s, 72 ◦C 10 s; 72 ◦C 3 min. Products of
the reactions were resolved in 1.5% agarose gel stained with ethidium bromide. PCR products with a
lower molecular weight than the wild type were selected for subsequent analysis. PCR products were
gel purified and cloned in the pGEM-T Easy vector (Promega, Madison, WI, USA). Ten independent
plasmid clones were sequenced using M13 universal primers. Products of Sanger sequencing
reactions were analyzed using the ABI 3130xl Genetic Analyzer (SB RAS Genomics Core Facility,
http://www.niboch.nsc.ru/doku.php/corefacility). Three clones containing deletions in the TDP1 gene
were found: Clone B2 ∆197bp/∆16bp+InT; clone B5 ∆198bp/∆196bp; and clone E3 ∆197bp/∆200bp.
To study the expression of the mutant form of TDP1 in clone E3, total RNA was isolated from cells
using TRIZOL reagent as per the manufacturer’s protocols. The synthesis of the first cDNA strand was
performed using SuperScript ™ III Reverse Transcriptase (ThermoFisher Scientific) according to the
manufacturer’s recommendations. To control DNA contamination of the RNA sample, a reaction was
performed without the addition of reverse transcriptase (RT-).
3.5. Cell Culture Assay
The cytotoxicity of the compounds was examined against human cell lines HEK293FT (human
embryonic kidney), WT and TDP1-deficient (TDP1-/-), HCT116 (human colon cancer), IMR-32 (human
neuroblastoma cell line), HeLa (cervical cancer), and Krebs-2 carcinoma ascites using MTT and EZ4U
colorimetric tests or an xCELLigence DP Real-Time Cell Analyzer (ACEA Biosciences, San Diego,
CA, USA) for HEK293FT in cells exposed to the compounds. The cells were grown in DMEM/F12 or
IMDM (for IMR-32 and Krebs-2) medium (Gibco), with 1x GlutaMAX (Gibco), 50 IU/mL penicillin,
50 µg/mL streptomycin (MP Biomedicals, Irvine, CA, USA) and in the presence of 10% fetal bovine
serum (Biolot). The cells (~20,000 cells per well) were incubated for 24 h at 37 ◦C in 5% CO2,
and then treated with the tested compounds (the volume of the added reagents was 1/100 of the
total volume of the culture medium, the amount of DMSO was 1% of the final volume as indicated).
Control cells were grown in the presence of 1% DMSO where indicated. After 72 h of cell incubation,
the relative amount of living cells was determined using a colorimetric test of the amount of formazan
converted from 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT test) or EZ4U
Cell Proliferation and Cytotoxicity Assay (Biomedica, Austria), as per the manufacturer’s protocols.
The real-time detection of the living cells was done by an xCELLigence DP Real-Time Cell Analyzer
(ACEA Biosciences). The measurements were carried out in three parallel experiments.
3.6. Calculation of Molecular Descriptors
The QikProp 3.2 [45] software was used to calculate the molecular descriptors of the ligands.
The reliability of QikProp is established for the calculated descriptors [46]. The known drug indexes
(KDI) were calculated from the molecular descriptors as described by Eurtivong and Reynisson [42].
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For application in Excel, columns for each property were created and the following equations used
do derive the KDI numbers for each descriptor: KDI MW: =EXP(-((MW-371.76)2)/((2 × 112.76)2)),
KDI Log P: =EXP(-((LogP-2.82)2)/((2 × 2.21)2)), KDI HD: =EXP(-((HD-1.88)2)/((2 × 1.7)2)), KDI HA:
=EXP(-((HA-5.72)2)/((2 × 2.86)2)), KDI RB- =EXP(-((RB-4.44)2)/((2 × 3.55)2)), and KDI PSA:
=EXP(-((PSA-79.4)2)/((2 × 54.16)2)). These equations could simply be copied into Excel and the descriptor
name (e.g., MW) substituted with the value in the relevant column. In order to derive KDI2A, this equation
was used: = (KDI MW + KDI LogP + KDI HD + KDI HA + KDI RB + KDI PSA) and for KDI2B: = (KDI
MW × KDI LogP × KDI HD × KDI HA × KDI RB × KDI PSA).
4. Conclusions
A new class of effective TDP1 inhibitors was discovered with activity in the low micromolar to
nanomolar concentrations. All the tested derivatives exhibited low intrinsic cytotoxicity when tested
in a panel of cancer cell lines. The most promising compounds with the best combination of TDP1
inhibition, low toxicity, and enhancement of Tpc efficacy were compounds 11h and 12k, with IC50
values of 0.75 and 1.20 µM, respectively. Thus, these new inhibitors are promising candidates for
adjuvant therapy, mainly due to the absence of an additional toxic load.
Furthermore, a panel of isogenic clones of the HEK293FT cell line knockout for TDP1 was created
using the CRISPR-Cas9 system. Clone E3 with the ∆197bp/∆200bp deletion in the TDP1 gene was
selected for the experiments. We investigated the cytotoxic effect of the Tpc and the TDP1 inhibitors
11h and 12k separately and jointly. HEK293FT TDP1-/- cells were more sensitive to Tpc compared to
WT cells. For both 11h and 12k, we observed cell growth suppression in the presence of Tpc only for
WT cells but not for the TDP1 knockout cells. It can therefore be stated that the synergistic effect with
Tpc on HEK293FT cell growth is only caused by TDP1 activity inhibition by 11h and 12k, with minimal
off-target effects. These results make a significant contribution to our understanding of the mechanism
of action for the non-cytotoxic 3-carene-derived TDP1 inhibitors. In conclusion, we demonstrated the
existence of TDP1 inhibitors, which do not modulate other biomolecular targets, which in turn makes
the prospect of developing viable drug candidates more realistic since off-target toxicity often leads to
undesirable side effects [47].
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